ArticleFrontiers in cardiovascular medicine2026
Is age still a barrier in ventricular tachycardia ablation? A study of safety, efficacy and clinical outcomes in the elderly.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ventricular tachycardia (VT) catheter ablation is an established therapy in patients with structural heart disease (SHD), yet its use in elderly populations remains limited due to concerns regarding procedural risk and outcomes. This study aimed to evaluate the safety, efficacy, and clinical outcomes of VT ablation across different age groups. Methods: We performed a retrospective analysis of 142 consecutive patients with SHD who underwent radiofrequency catheter ablation (RFCA) for sustained monomorphic VT between 2013 and 2025. Patients were stratified into three age groups: ≤64 years ( Results: Acute procedural success rates were similar across age groups (complete success: 76.05% vs. 72.5% vs. 77.42%, Conclusions: VT ablation in elderly patients with SHD demonstrates comparable procedural safety and arrhythmic efficacy to younger populations. However, advanced age is associated with worse long-term outcomes, likely reflecting a higher burden of comorbidities. These findings support an individualized approach to patient selection, where age alone should not preclude consideration for VT ablation in appropriately selected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.